Spotlight On... WIRB-Copernicus buys Clintrax; Evotec hits a biotech milestone; and more...

Pharma contractor WIRB-Copernicus Group acquired Clintrax Global, a company that specializes in helping CROs and sponsors negotiate clinical trial contracts. Founded in 2013, Clintrax has handled negotiations in more than 65 countries, the company said, managing payments between parties in the clinical development process. WIRB-Copernicus, which offers similar services, said adding Clintrax would expand its global reach and help it compete for more clients. Release

> German service provider Evotec hit a preclinical milestone with biotech partner Padlock Therapeutics, triggering a "significant" payment in a deal that could pay out more than $13 million, the company said. News

> Biologics signed on to distribute BTG International's recently approved Vistogard in the U.S. Item

Suggested Articles

Data firm Syapse has begun working with the FDA to help bring real-world evidence to bear on the agency’s decisions to approve cancer drugs.

The People-Centered Research Foundation tapped Datavant to de-identify real-world data across its national clinical research network.

Boehringer Ingelheim and MD Anderson Cancer Center have joined forces to create a “virtual” R&D hub so the pair can work on cancer drugs.